Works in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, Vol 20, Issue S6

Results: 275
    1
    2
    3
    4

    Heneicosapentaenoic acid, a metabolite resulting from the α‐oxidation of α‐Hydroxy‐Docosahexaenoic Acid, exerts neuroprotection against Alzheimer's disease and reduces astrocytic mitochondrial activity.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.092724
    By:
    • Cabot, Joan;
    • Parets, Sebastià;
    • Miralles, Marc;
    • Trujillo‐Estrada, Laura;
    • Gutierrez, Antonia;
    • Fernández‐García, Paula;
    • Lladó, Victoria;
    • Escriba, Pablo V.;
    • Torres, Manuel
    Publication type:
    Article
    5

    Low Incidence of Amyloid Related Imaging Abnormalities over 104 Weeks in a Phase 2 Study of Amyloid Anti‐Oligomer Agent ALZ‐801: Phase 2 Study Results in Biomarker Positive APOE4 Carriers with Early Alzheimer's Disease (AD).

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.092653
    By:
    • Kesslak, Patrick;
    • Abushakra, Susan;
    • Bracoud, Luc;
    • Hey, John A.;
    • Barakos, Jerome;
    • Hort, Jakub;
    • Prins, Niels D.;
    • Suhy, Joyce;
    • Power, Aidan;
    • Tolar, Martin
    Publication type:
    Article
    6

    Issue Information.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.13337
    Publication type:
    Article
    7

    Understanding the gut‐brain axis to mitigate cognitive frailty.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.093563
    By:
    • Majeed, Abu Bakar Abdul;
    • Ramasamy, Kalavathy;
    • Tan, Maw Pin;
    • LIm, Siong Meng;
    • Hui, Khor Min;
    • Tan, Ai Huey;
    • Fadzuli, Nurul Izzati Ahmad
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16

    Protective mechanism of APOE3‐Christchurch in Alzheimer's disease.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.093237
    By:
    • Raulin, Ana‐Caroline;
    • Linares, Cynthia;
    • Alnobani, Alla;
    • Roy, Bhaskar;
    • Crow, Ailsa;
    • Doss, Sydney V.;
    • Kuchenbecker, Lindsey A;
    • Dacquel, Maxwell V;
    • Karch, Celeste M.;
    • Martens, Yuka A;
    • Liu, Chia‐Chen;
    • Bu, Guojun;
    • Kanekiyo, Takahisa
    Publication type:
    Article
    17
    18

    Acute Aβ12‐28P administration targeting apoE/Aβ interaction rescues synaptic function and cognitive decline in advanced‐stage Alzheimer's disease.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.093081
    By:
    • Chen, Shuo;
    • Lam, Nikolas;
    • Li, Zhiheng;
    • Wang, Ding;
    • Liu, Pengfu;
    • Berbano, Victoria;
    • Xie, Yu;
    • Nguyen, Tyra;
    • Xu, Yvonne;
    • Yang, John;
    • Ha, Karen;
    • Semana, Leonardo;
    • Dias, Rachel;
    • Masurkar, Arjun V.;
    • Wisniewski, Thomas
    Publication type:
    Article
    19
    20

    Phase 2 Study Results of Oral ALZ‐801 (Valiltramiprosate) in Early Alzheimer's Disease Shows Potential Disease Modification Effect: 2‐Year Effect on Plasma Biomarkers, Volumetric MRI, Cognition Outcomes and Clinical Benefit Analysis.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.092950
    By:
    • Hey, John A.;
    • Abushakra, Susan;
    • Blennow, Kaj;
    • Kesslak, Patrick;
    • Hort, Jakub;
    • Prins, Niels D.;
    • Sheardova, Katerina;
    • Schaefer, Jean;
    • Albayrak, Adem;
    • Pak, Winnie;
    • Power, Aidan;
    • Tolar, Martin
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Results from a Phase 2a Proof‐of‐Concept Double‐Blind, Randomized, Placebo‐Controlled Trial of Lomecel‐B<sup>TM</sup> in Mild Alzheimer's Disease Dementia.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.092295
    By:
    • Ramdas, Kevin N.;
    • Agafonova, Nataliya;
    • Hare, Joshua M.;
    • Naioti, Eric;
    • Kopcho, Steven;
    • Cummings, Jeffrey L.;
    • Carballosa, Raul;
    • Patel, Paayal;
    • Brody, Mark;
    • Herskowitz, Brad;
    • Fuquay, Ana;
    • Rodriguez, Savannah;
    • Botbyl, Jeffrey;
    • Rash, Brian;
    • Oliva, Anthony A.
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44

    A Seamless Phase 2A‐Phase 2B Multi‐Center Trial to Test the Benefits of Benfotiamine on the Progression of Alzheimer's Disease‐Benfoteam: Design and Methods.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.091963
    By:
    • Luchsinger, Jose A.;
    • Feldman, Howard H.;
    • Messer, Karen;
    • Edland, Steven D.;
    • Leger, Gabriel C;
    • Jacobs, Diane M.;
    • Salmon, David P.;
    • Revta, Carolyn;
    • Lupo, Jody‐Lynn;
    • Durant, January;
    • Gibson, Gary E.
    Publication type:
    Article
    45
    46
    47

    Lecanemab Slows Tau PET Accumulation.

    Published in:
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.091956
    By:
    • Charil, Arnaud;
    • Cao, Youfang;
    • Willis, Brian A.;
    • Hersch, Steven;
    • Irizarry, Michael C.;
    • Reyderman, Larisa
    Publication type:
    Article
    48
    49
    50